| INTRODUCTION
Chronic hepatitis (CH) is a common liver disease in dogs and is histologically characterized by hepatocellular apoptosis or necrosis, a variable mononuclear or mixed inflammatory cell infiltrate, and the presence of fibrosis. 1, 2 Liver biopsy is the gold standard for diagnosing chronic liver diseases, and necro-inflammatory activity (grade) and amount of fibrosis (stage) can be scored histopathologically. 3 Liver fibrosis is defined as increased deposits of extracellular matrix (ECM)
proteins. 4 Deposited ECM proteins include fibrillary collagens, nonfibrillary collagens, glycosaminoglycans, and proteoglycans. 5 Liver cirrhosis (LC) is the result of an accumulation of ECM accompanied by disruption of the hepatic architecture and the presence of Abbreviations: ALT, alanine aminotransferase; BA, bile acids; CH, chronic hepatitis; ECM, extracellular matrix; HSCs, hepatic stellate cells; LC, liver cirrhosis; NL, normal liver; TGF-β1, transforming growth factor β1. 
| MATERIALS AND METHODS

| Animals
| Blood samples
Blood samples were obtained from all dogs before the liver biopsy.
ALT and fasting bile acids (BA) concentrations were measured in heparinized plasma at the time of diagnostic workup at the Veterinary Diagnostic Laboratory of Utrecht University (UVDL). Reference range for ALT and fasting BA were established by UVDL and are <70 U/L and <10 μmol/L, respectively. Serum samples were stored at −20 C or −70 C until microRNA analysis.
| Histopathology
Liver biopsies were taken with a 14-G needle using a Tru-Cut device under ultrasound guidance and processed as described previously. miR-specific primer (Qiagen), and 1 μL of the previously diluted cDNA.
The total reaction volume of each PCR was adjusted to 10 μL by adding 2 μL RNase-free water. The concentrations of all microRNAs were quantified using absolute quantification via a standard curve, with quantities normalized to the synthetic C. elegans miR-39 as spike-in control. 35 
| Statistical analysis
All data of dog characteristics were reported as median (range). The overall difference among groups was determined using the nonpara- 3 | RESULTS
| Characteristics of Labrador Retrievers
Serum samples of 22 Labrador Retrievers were analyzed. Characteristics of the NL group (n = 7), CH group (n = 8), and LC group (n = 7)
are shown in Table 1 .
| Serum microRNAs are associated with liver fibrosis in Labrador Retrievers
The analysis of circulating microRNAs associated with the grade of hepatitis and the stage of fibrosis is provided in Table 2 . Upon univariate analysis, both miR-122 and miR-29a were significantly associated with the grade of hepatitis and the stage of fibrosis (P < .001 for all analyses). These microRNAs were also statistically significant upon multivariate analysis. Neither of the microRNAs was significantly associated to copper scoring upon multivariate analysis.
A positive correlation was identified between the grade of hepatitis with miR-122 (r s = 0.79, P < .001; Figure 1A ) and miR-29a (r s = 0.78, P < .001; Figure 1B ). Both miR-122 (r s = 0.81, P < .001; Figure 2A ) and miR-29a (r s = 0.67, P < .001; Figure 2B ) showed a significant positive correlation with the stage of fibrosis. On histological stage, circulating miR-122 concentrations were significantly higher in the LC group than in the NL (P < .001) and CH (P < .05) groups ( Figure 3A ) and were significantly higher in the CH group than in the NL group (P < .01). Circulating miR-29a concentrations were not detected in the NL group and were highly expressed in the CH and LC groups ( Figure 3B ).
Circulating miR-122 and miR-29a concentrations in 2 Labrador
Retrievers with different disease stage are shown in Table 3 . Circulating miR-122 concentrations were increased in dog 1 upon progression form NL to CH and were decreased in dog 2 (progression CH to LC) in parallel with plasma ALT concentrations. Circulating miR-29a concentrations were increased in both dogs with a worsened stage of fibrosis.
| DISCUSSION
Liver cirrhosis, the end stage of CH, carries a very poor prognosis in dogs. 5, 7, 8 Therefore, a liver biopsy is often recommended for early diagnosis and treatment although this invasive technique carries some risk. 6, 18 Therefore, efforts have been made to investigate the Data are expressed as median (range). Abbreviations: ALT, alanine aminotransferase; BA, bile acids; CH, chronic hepatitis; F, female; FS, female spayed; LC, liver cirrhosis; NL, normal liver; M, male; MC, male castrated. *P < .05 compared with NL.; **P < .01 compared with NL.; ***P < .001 compared with NL.
possibilities for using noninvasive biomarkers to monitor disease progression. Mature microRNAs are emerging as biomarkers for hepatobiliary diseases in humans because they can be detected and quantified in the blood. [21] [22] [23] MicroRNAs can be used as diagnostic markers for hepatocellular injury and hepatobiliary diseases in Labrador Retrievers and other canine breeds. 24, 25 Because various microRNAs also play essential roles in hepatic fibrogenesis such as hepatic stellate cell (HSC) activation, HSC proliferation, and ECM deposition, microRNAs may serve as markers of disease progression. 26, 36 Thus, we assessed in our study whether circulation microRNAs can be used as biomarkers to monitor the grade and stage of CH in Labrador Retrievers.
Circulating microRNAs have been reported as biomarkers of liver injury in various forms of human liver diseases such as chronic viral hepatitis, nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, cholestasis, and hepatocellular carcinoma, and their concentrations have been correlated with the severity of the disease. [21] [22] [23] 26 Because most microRNAs show a high level of similarity in dogs and humans, 37 there is a possibility that circulating microRNAs in dogs can also be used as biomarkers for disease progression in CH. Thus, we selected 5 candidates of circulating microRNAs as biomarkers for fibrosis progression including miR-122, miR-29a, miR-133a, miR-181b, and miR-17-5p based on the current available human literature. [30] [31] [32] [33] [34] As a result, we observed that miR-122 and miR-29a correlated with the grade of hepatitis and the stage of fibrosis. The serum concentrations of miR-133a, miR-181b, and miR-17-5p were increased in human patients with LC. 31, 33, 34 However, these circulating microRNAs were not significantly associated with the grade and stage in our dogs. In a study on circulating microRNAs as biomarkers of chronic heart diseases in Dachshunds,
Hulanicka et al concluded that the microRNA findings from dogs
were not directly reflected in human medicine. 38 Thus, circulating microRNA concentrations in Labrador Retrievers with CH might also differ between species and disease type.
Mature miR-122 has been characterized as a hepatocyte-derived microRNA, accounting for about 70% of all hepatic microRNAs.
23
Serum miR-122 concentrations were increased in acute liver injury and was an earlier marker of hepatocellular damage than serum ALT activity in humans. 22, 23 Circulating miR-122 values were increased in Beagle dogs with acute hepatocellular necrosis induced by hepatotoxic compounds in the absence of increases in ALT. 37, 39 Our previous reports demonstrated that circulating miR-122 is a highly sensitive marker for the detection of hepatocellular injury in Labrador Retrievers, 24 and it is increased in dogs with acute and CH. 25 Retrievers and tended to be higher in CH compared to AH in dogs. 24, 25 Plasma ALT activity in our study was high in dogs with the LC group as well as the CH group. This suggests that the inflammatory activity was maintained in dogs with LC and indicates that the release FIGURE 3 Circulating miR-122 (A) and miR-29a (B) concentrations in Labrador Retrievers with normal liver (NL, n = 7), chronic hepatitis (CH, n = 8), and liver cirrhosis (LC, n = 7). *P < .05, **P < .01, ***P < .001 Abbreviations: ALT, alanine aminotransferase; BA, bile acids; CH, chronic hepatitis; LC, liver cirrhosis; NL, normal liver.
